Preferred Name |
sulfasalazine |
|
Synonyms |
sulphasalazine Azulfidine 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid salazosulfapyridine |
|
Definitions |
A synthetic salicylic acid derivative with affinity for connective tissues containing elastin and formulated as a prodrug, antiinflammatory sulfasalazine acts locally in the intestine through its active metabolites, sulfamide 5-aminosalicylic acid and salicylic acid, by a mechanism that is not clear. It appears inhibit cyclooxygenase and prostaglandin production and is used in the management of inflammatory bowel diseases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29469" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29469" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000685032 |
|
altLabel |
sulphasalazine Azulfidine 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid salazosulfapyridine |
|
CAS Registry |
599-79-1 |
|
cui |
C0036078 C0699547 |
|
DATE FIRST PUBLISHED |
2010-09-07 |
|
Date last modified |
2010-09-07 |
|
definition |
A synthetic salicylic acid derivative with affinity for connective tissues containing elastin and formulated as a prodrug, antiinflammatory sulfasalazine acts locally in the intestine through its active metabolites, sulfamide 5-aminosalicylic acid and salicylic acid, by a mechanism that is not clear. It appears inhibit cyclooxygenase and prostaglandin production and is used in the management of inflammatory bowel diseases. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29469" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29469" NCI Thesaurus) |
|
LT |
TRD |
|
NCI ID |
C29469 |
|
notation |
CDR0000685032 |
|
NSC Code |
667219 203730 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
sulfasalazine |
|
tui |
T109 T121 |